Predictors of relapse after withdrawing biotherapies in children with inactive juvenile idiopathic arthritis: a retrospective cohort study of the JIR cohort
Authors' conclusion
Relapses are common after discontinuing biologic therapies in JIA, particularly in patients with antinuclear antibody positivity and psoriatic arthritis and those who stop treatment shortly after reaching inactive disease status.
Study context
- Population
- Juvenile idiopathic arthritis (JIA) patients in the JIR cohort, two French tertiary centres, who discontinued biologic/targeted synthetic DMARDs (2000–2023) after remission (Wallace criteria)130 discontinuations analysed
- Participants
- 115 patients
- Exposure
- Psoriasis vs Systemic
- Psoriasisn = 19
- Systemicn = 21
- Outcome
- Relapse within 1 year after treatment withdrawal
- Follow-up
- 1 year
Methodological detailstwo French tertiary centres, JIR cohort, multivariate regression
- Two French tertiary centres
- JIR cohort
- Multivariate regression
Main finding
As reported in the abstract
- Relapse within 1 year (all discontinuations)
- 56.2% (73/130)
- Increased probability of relapse with ANA positivity at diagnosis
- p < 0.05
Observational data: associations, not effects.
Further findings
Relapse within 1 year by JIA subgroup · highest (psoriasis) and lowest (systemic) relapse rates
Original publication
Predictors of relapse after withdrawing biotherapies in children with inactive juvenile idiopathic arthritis: a retrospective cohort study of the JIR cohort. Pediatr Rheumatol Online J. Published 20 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →